Search

Objective: To review the results and expectations of contemporary stereotactic radiosurgery., Material and Methods: We conducted a retrospective analysis of 1,033 consecutive patients who underwent gamma knife radiosurgery at Mayo Clinic Rochester between January 1990 and January 1998., Results: The number of patients undergoing radiosurgery increased from 57 in 1990 to 216 in 1997. Of 97 patients with arteriovenous malformations who underwent follow-up angiography 2 years or more after a single radiosurgical procedure, 72 (74%) had complete obliteration of the vascular malformation. Of 209 patients who underwent radiosurgery for benign tumors (schwannomas, meningiomas, or pituitary adenomas) and had radiologic studies after 2 years or more of follow-up, tumor growth control was noted in 200 (96%). Tumor growth was also controlled in 90% of brain metastatic lesions at a median of 7 months after radiosurgery. Of 20 patients with trigeminal neuralgia and follow-up for more than 2 months, 14 (70%) were free of pain after radiosurgery., Conclusion: Radiosurgery is a safe and effective management strategy for a wide variety of intracranial disorders. Use of radiosurgical treatment should continue to increase as more data become available on the long-term results of this procedure.

With the increasing utilization of permanent brachytherapy implants for treating carcinoma of the prostate, the importance of accurate post-treatment dose calculation also increases for assessing patient outcome and planning future treatments. An automatic method for seed localization of permanent brachytherapy implants, using CT datasets of the prostate, has been developed and tested on a phantom using an actual patient planned seed distribution. This method was also compared to results with the three-film technique for three patient datasets. The automatic method is as accurate or more accurate than the three film technique for 1 mm, 3 mm, and 5 mm contiguous CT slices, and eliminates the inter- and intra-observer variability of the manual methods. The automated method improves the localization of brachytherapy seeds while reducing the time required for the user to input information, and is demonstrated to be less operator dependent, less time consuming, and potentially more accurate than the three-film technique.

Purpose: Two developments in 125I-sealed source dosimetry have necessitated swift and accurate implementation of TG43 dosimetry in clinic: (a) the dosimetry constants of 125I endorsed by the AAPM Task Group 43 Report result in calculated dose rate that deviates by as much as 15% from currently accepted dose-rate distributions, and (b) The National Institute of Standards and Technology (NIST) has proposed modifying the 125I air-kerma strength standard by approximately 10%., Methods and Materials: The ad hoc committee of AAPM Radiation Therapy Committee describes specific procedures to implement these two developments without causing confusion and mistakes., Conclusions: Confusion and mistakes may be avoided when the following two general steps are taken: 1) STEP I, TG-43 implementation, and 2) STEP II, new air-kerma strength standard implementation when available from NIST.

Purpose: To assess the efficacy and toxicity of stereotactic radiosurgery using the gamma knife for acoustic neuromas., Methods and Materials: Between January 1990 and January 1993, 36 patients with acoustic neuromas were treated with stereotactic radiosurgery using the gamma knife. The median maximum tumor diameter was 21 mm (range: 6-32 mm). Tumor volumes encompassed within the prescribed isodose line varied from 266 to 8,667 mm3 (median: 3,135 mm3). Tumors < or = 20 mm in maximum diameter received a dose of 20 Gy to the margin, tumors between 21 and 30 mm received 18 Gy, and tumors > 30 mm received 16 Gy. The dose was prescribed to the 50% isodose line in 31 patients and to the 45%, 55%, 60%, 70%, and 80% isodose line in one patient each. The median number of isocenters per tumor was 5 (range: 1-12)., Results: At a median follow-up of 16 months (range: 2.5-36 months), all patients were alive. Thirty-five patients had follow-up imaging studies. Nine tumors (26%) were smaller, and 26 tumors (74%) were unchanged. No tumor had progressed. The 1- and 2-year actuarial incidences of facial neuropathy were 52.2% and 66.5%, respectively. The 1- and 2-year actuarial incidences of trigeminal neuropathy were 33.7% and 58.9%, respectively. The 1- and 2-year actuarial incidence of facial or trigeminal neuropathy (or both) was 60.8% and 81.7%, respectively. Multivariate analysis revealed that the following were associated with the time of onset or worsening of facial weakness or trigeminal neuropathy: (a) patients < age 65 years, (b) dose to the tumor margin, (c) maximum tumor diameter > or = 21 mm, (d) use of the 18 mm collimator, and (e) use of > five isocenters. The 1- and 2-year actuarial rates of preservation of useful hearing (Gardner-Robertson class I or II) were 100% and 41.7% +/- 17.3, respectively., Conclusion: Stereotactic radiosurgery using the gamma knife provides short-term control of acoustic neuromas when a dose of 16 to 20 Gy to the tumor margin is used. Preservation of useful hearing can be accomplished in a significant proportion of patients.

This retrospective study analyzed the outcome of lung cancer patients who were treated with either 4-MV or 10-MV photons. From October 1979 through December 1982, 126 patients with locally advanced, unresectable or medically inoperable, nonmetastatic non-small cell lung cancer were treated in a prospective trial in which they were randomly assigned to one of three chemotherapy combinations and thoracic radiotherapy. The patients were stratified by cell type, extent of operation, age, sex, and status of supraclavicular lymph nodes. All patients were followed until death or for a minimum of 4.8 years. Of the 102 evaluable patients, 98 were treated with either 4-MV or 10-MV photons (49 patients in each group). Outcomes examined included best primary tumor response, time to first local (in-field) recurrence, disease-free survival, and overall survival. No significant differences were detected between the patients treated with 4-MV or 10-MV photons for several important prognostic and treatment factors or for any of the study outcomes, including first local (in-field) recurrence, disease-free survival, and overall survival. For the group of 98 patients treated with either 4-MV or 10-MV photons, the estimated 2-year freedom from first local (in-field) recurrence was 47.7%. The estimated 2-year disease-free and overall survivals were 21.6% and 28.6%, respectively.

The TG-21 protocol recommends using a thin sheath for waterproofing an ion chamber used in the calibration of photon and electron beams. A thickness of 0.5 mm is suggested for a material having a composition and density close to that of water. This work investigates the effect on the calibration of photon beams ranging from Co60 to 25 MV, and electron beams ranging from nominal energies of 7-18 MeV, for changes in the thickness of the waterproofing sheath from 0.5 to 5.5 mm. For photon beams, a maximum change of 1.2% was found for the 25-MV x-ray beam. For electron beams, a maximum change of 0.5% was found for 10-MeV electrons. It is concluded that the thickness of the waterproofing sheath is not a very sensitive variable, assuming the thickness is between 0.5 and 2.0 mm.

A comparison between the Manchester System and the Paris System of interstitial dosimetry has been made in the case of single and double plane implants. The rules of both systems are reviewed. A brief description of the Paris System is presented in an appendix. Dose distributions for two different examples are presented in two orthogonal planes. The Paris System uses considerably fewer sources than the Manchester System. It results in a larger volume of high dose than the Manchester System. The use of Iridium-192 sources strength and source length can be adjusted represents a significant advantage. The Paris System attempts to adapt the implant configuration to the clinical situation as the target thickness is used to define the source separation and the target length is used to define the source length. The differences in the dose definition are discussed.

Portal localization films are taken in order to assure the accurate placement of the treatment field relative to the patient anatomy. This is routinely done for photon fields and maybe for electron fields. This paper describes a technique which uses the bremsstrahlung component of an electron beam of energy 10 MeV and greater to expose a film to image a treatment port. These films provide verification of the placement of the electron field and document the treatment of a specific area.

Total skin low energy electron beam irradiation is used to treat superficially widespread skin lesions such as cutaneous T-cell lymphoma. Total skin irradiation involves delivering an adequate dose at a depth of 0.25 to 1.0 cm, while sparing underlying tissue. The dose distributions obtained when using a modified Stanford six-field technique depend upon the beam energy, the beam angle, the diameter and shape of the body part, and other variables. The dose distribution uniformity of six pairs of angulated electron beams has been studied as a function of beam energy, the gantry angle, +/- theta, above and below the horizontal and the diameter of a cylindrical polystyrene phantom. Depth doses and dose uniformity for single and multiple fields have been measured as a function of beam energy, phantom diameter and position.

The characteristics of very small fields, 1 X 1 and 2 X 2 cm, of electron beams of nominal energies, 5, 7, 10, 12, 15, and 18 MeV have been studied and compared to a 10 X 10 cm field. A parallel-plate ion chamber and film have been used to obtain various dose parameters. The central axis depth dose measurements, field flatness, uniformity index, and relative output factors are presented. It was found that satisfactory results for determining the relative output factor can be obtained from film data using a scanning densitometer. It is our conclusion that film dosimetry is acceptable in determining the necessary clinical parameters needed to treat patients with fields as small as 2 X 2 cm. For the 1 X 1 cm field size and for the electron energies greater than 10 MeV, there was substantial disagreement between the ion chamber and film data in the buildup region as well as the regions beyond the depth of maximum dose to the depth of 90% dose.

A calculation is described that enables the rapid assessment of dose rate at various points of interest within the eye (lens, optic nerve, etc.) for the treatment of choroidal melanoma by plaque therapy. 125I seeds are used as the radiation source. The location of the plaque and its associated seeds relative to the eye (in a Cartesian coordinate system) is determined from the description of the tumor, as drawn and dimensioned on a fundus-view diagram by the ophthalmologist. This requires a computer to numerically solve an equation, which is derived in the framework of spherical geometry. Further results of this calculation yield data files that serve as the input to a conventional brachytherapy treatment planning program. This enables the visualization of the dose distribution within a plane that contains the major axis of the tumor in order to assess the adequacy of the treated volume.

Serial biopsies of the prostate after high dose external irradiation for adenocarcinoma show a gradual disappearance of the neoplastic cells. With such treatment, results of the biopsies do not have any short term prognostic significance. However, positive biopsies 12 months or more after treatment are reputed to be an unfavorable sign for long-term survival. From August, 1970 through February, 1974, 46 consecutive patients with locally advanced (Stage III, C, or T3 and T4) adenocarcinoma of the prostate underwent external irradiation with 2 MV X rays or cobalt-60 teletherapy. The technique included parallel, opposed, 14 X 14 cm anterior and posterior fields, and a 10 X 14 cm perineal field. The center of the prostate received a total dose of 70 Gy in 30-37 fractions in 43 to 56 days. Details of the dosimetry reveal inhomogeneity of the dose of +/- 7% within an enlarged prostate. With a median follow-up of 8 years, the actuarial survival rates, uncorrected for death from intercurrent disease, are 69% at 5 years and 49% at 10 years. Biopsies of the prostate 12 months or more after treatment were available from 31 patients: 19 had one or more positive biopsies and 12 had consistently negative biopsies; the survival curves are identical for those with and those without positive biopsies. Prostatic biopsies obtained 24 months or more after treatment were available from 21 patients: 10 had positive and 11 had negative biopsies; the survival curves are identical for those with and without residual cancer cells. Following adequate irradiation of patients with locally advanced adenocarcinoma of the prostate, the results of biopsies obtained one or two years after treatment do not predict long-term survival.

The dosimetry of 192Ir linear sources with a commercial treatment planning computer system has been evaluated. Reference dose rate data were selected from the literature and normalized in a manner consistent with our clinical and dosimetric terminology. The results of the computer calculations are compared to the reference data and good agreement is shown at distances within about 7 cm from a linear source. The methodology of translating source calibration in terms of exposure rate for use in the treatment planning computer is developed. This may be useful as a practical guideline for users of similar computer calculation programs for iridium as well as other sources.

An independent primary dose counter or totalizer has been developed for our linear accelerator. This counter is reset independently of the control console and thus will totalize the number of monitor units (MUs) delivered to the patient. This is especially useful for patients being treated at extended distances when it is necessary to reset the control console several times. The independent totalizer does not load down the control console dosimetry circuit and can be adapted to the digital logic used. The details of the system will be presented.

Following the recommendations of the European Curietherapy Group, the three-dimensional dose distribution corresponding to various milligram-hour volumes has been analyzed according to its length, width, and height dimensions. Thus, it is possible to state the dimensions of a number of isodose surfaces for a dose prescription given in milligram-hours. Problems associated with the exact placement of the three-dimensional dose distribution in relation to the patient's anatomy are discussed.